drugset / Trial / NCT01546116

Adefovir and Lamivudine for Entecavir Resistance (ALTER Study)

NCT01546116

Phase 4 Completed 20 enrolled Korea University GlaxoSmithKline · collab
NaSingle-groupOpen-labelTreatment

Summary

* Entecavir has been one of the option for treatment of lamivudine resistant chronic hepatitis B (CHB). * In case of entecavir resistance, adefovir could be used. However, sequential monotherapy may result in multidrug resistance. * It is thought that adefovir and lamivudine combination therapy reduce the risk of adefovir resistance, thereby continued therapy will lead to suppression of hepatitis B virus (HBV) DNA to be undetectable in patients with entecavir resistance. * This study aim to evaluate the efficacy of adefovir and lamivudine combination therapy in CHB patients with entecavir resistance.

Timeline

Start
2010-02
Primary completion
2012-02
Completion
2014-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Adefovir Unknown 10 mg
Subject Lamivudine Other / unclassified 100 mg